anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting.
METHODS: This single-arm clinical trial is being conducted under an FDA investigational device exemption (IDE) approved for 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine. Treatment will be 8 Gy in a single fraction administered at ≥ 40 Gy/s on a FLASH-enabled proton therapy system delivering a single transmission proton beam. Primary study endpoints are efficacy (pain relief) and safety. Patient questionnaires evaluating pain flare at the treatment site will be completed for 10 consecutive days post-RT. Pain response and adverse events (AEs) will be evaluated on the day of treatment and on day 7, day 15, months 1, 2, 3, 6, 9, and 12, and every 6 months thereafter. The outcomes for clinical workflow feasibility are the occurrence of any device issues as well as time on the treatment table.
DISCUSSION: This prospective clinical trial will provide clinical data for evaluating the efficacy and safety of proton FLASH for palliation of bony metastases in the thorax. Positive findings will support the further exploration of FLASH radiation for other clinical indications including patient populations treated with curative intent.
REGISTRATION: ClinicalTrials.gov NCT05524064.
The purpose of the present invention is to provide an inkjet ink which is less in discoloration with time and can print in a stable color not only when printing on the surface of a print target object having relatively low ink permeability but also when printing on the surface of a print target object having relatively high ink permeability, and a print target object having a print portion printed with the inkjet ink. The gray ink of the present embodiment is an ink for inkjet having edibility, and contains at least a 1 st coloring matter as an edible dye and a 2 nd coloring matter as an edible dye, and the 1 st coloring matter is at least 1 of red No. 3, red No. 40, red No. 104, red No. 105, and red No. 106.
Embodiments of the disclosure provide methods and systems for disease condition prediction from images of a patient. The system may include a communication interface configured to receive a sequence of images acquired of the patient by an image acquisition device. The sequence of images are acquired at a sequence of prior time points during progression of a disease. The system may include a processor, configured to determine regions of interest based on the sequence of images. The processor applies a progressive condition prediction network to the regions of interest to predict a level of disease progression at a future time point during the progression of the disease. The progressive condition prediction network predicts the level of disease progression based on the regions of interest and disease conditions at the sequence of prior time points. The processor further provides a diagnostic output based on the predicted level of disease progression.
Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
Although the majority of RA patients achieve an amelioration of their RA with older disease modifying agents such as methotrexate and leflunomide, all of these agents provoke adverse events. The newer more active biological agents have a distinct safety profile that includes an increased risk of serious infections. They have an annual treatment expense in the tens of thousands of dollars a year. PRTX-100 may be able to modify the disease course of rheumatoid arthritis with an improved safety profile compared to available agents and a dosing regimen comparable to the therapies currently available. This study is done to describe the adverse event profile of 6 μg/kg of PRTX-100 administered IV for longer periods of treatment that might be required for RA therapy. Secondary objectives include: evaluation of the clinical response of subjects with previous administration of PRTX-100; evaluation of anti-PRTX antibody presence and effect on activity; evaluation of "Power Doppler" ultrasound in the assessment of joint inflammation; and evaluation of biomarkers.

Assay development is an intrinsic part of drug and biological development. The current assay for anti-PRTX-100 antibodies depends on a very limited supply of serum available from individuals in early trials. It will be necessary to obtain adequate antisera to provide immunological reagents for this assay. It is not known whether the character of anti-PRTX-100 antibodies from volunteers is similar to those produced by patients with immunological disorders on cytotoxic therapy. Antisera will be developed in normal volunteers. The anti-PRTX-100 antibody assay will need to be standardized with a new anti-PRTX-100 antibody source compared to the present human reagent.
Acute myeloid leukemia (AML) is a malignant hematological disorder in which aberrant cytokine signaling and inflammation play a role in disease initiation and progression. Interleukin-40 (IL-40) is a novel cytokine encoded by the chromosome 17 open reading frame 99 (C17orf99) gene. This cytokine is involved in mediating inflammation but its biological significance in the pathogenesis of AML has not been investigated. In this case-control and observational study, mRNA expression and DNA methylation of the C17orf99 gene were evaluated in the peripheral blood of AML patients. In addition, the polymorphism of two novel intergenic variants of the C17orf99 gene, rs2004339 A/G and rs2310998 G/A, were explored using a real-time polymerase chain reaction assay. The study was conducted on 131 patients with AML and 106 controls and gene expression and DNA methylation were expressed as fold-change (2-ΔΔCt). Results revealed that mRNA expression of the C17orf99 gene was down-regulated in AML patients, particularly in females, while up-regulated expression was found in patients with hypoalbuminemia. For DNA methylation, it was up-regulated in AML patients, particularly in females, AML M5 subtype, and CD4-negative and CD14-positive peripheral blood cells. The mutant A allele and the corresponding homozygous AA genotype of rs2004339 was significantly associated with an increased risk of AML. The AA genotype was also associated with significantly up-regulated C17orf99 mRNA expression and DNA methylation of compared to the wild-type GG genotype. In conclusions, C17orf99 mRNA expression showed down-regulated levels in the peripheral blood of AML patients, while DNA methylation was up-regulated. The intergenic variant rs2004339 was associated with susceptibility to AML and had an effect on mRNA expression and DNA methylation.
It is intended to develop a heterodimer by which a complex of receptor and/or ligand-binding proteins of different molecular species with a ligand can be formed. A heterodimer consisting of a first subunit containing the extracellular domain of the IL-1 receptor type II and a first chemical part and a second subunit containing the extracellular domain of IL-1 receptor accessory protein and a second chemical part, wherein the first chemical part and the second chemical part make the first subunit and the second subunit to associate together to thereby form a complex capable of binding to an IL-1 ligand, is provided. The above-described heterodimer contains a polypeptide having an amino acid sequence represented by SEQ ID NO:34 or 37, etc. and another polypeptide having an amino acid sequence represented by any of SEQ ID NOS:43 to 47 and the above-described IL-1 receptor accessory protein Ig-fused protein is characterized by containing a polypeptide having an amino acid sequence represented by SEQ ID NO:35 or 38, etc. and another polypeptide having an amino acid sequence represented by any of SEQ ID NOS:43 to 47, etc. in some cases.
Suprax® 100 mg/5 mL dry syrup was dissolved by 33 mL of water split in 2 portions. Then the drug was shaken well for at least 30 seconds at each addition of water.
The present invention relates to a mask sheet put on skin and used for supplying moisture and nutrition. More specifically, the mask sheet includes a shape memory polymer, so a shape is transformed under a predetermined condition. According to the mask sheet and a method thereof of the present invention, the mask sheet includes a shape memory polymer, so a shape is transformed and the mask sheet is fixed under a predetermined condition. The mask sheet distributed in a small size may be put after being transformed corresponding to a size and a shape of a user′s face, and a shape thereof is fixed after being put, so the mask sheet does not slip down. Moreover, according to the present invention, a dotted cutting line is formed on the mask sheet, so the length after separation may be adjusted. In addition, a moisture protective film is further formed on one surface of a shape transforming unit which directly adheres to skin, so moisture can be prevented from being evaporated when the shape transforming unit adheres to skin.
The following is based on the little information available concerning overdosage with meclofenamate sodium and related compounds. After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.

Management consists of emptying the stomach by emesis or lavage and instilling an ample dose of activated charcoal into the stomach. There is some evidence that charcoal will actively absorb meclofenamate sodium, but dialysis or hemoperfusion may be less effective because of plasma protein binding. The seizures should be controlled by an appropriate anticonvulsant regimen. Attention should be directed throughout, by careful monitoring, to the preservation of vital functions and fluid-electrolyte balance. Dialysis may be required to correct serious azotemia or electrolyte imbalance.
BACKGROUND: The gut microbiota may be involved in neuropathic pain. However, the causal association between gut microbiota and neuropathic pain remains unclear. Whether immune cells and inflammatory factors mediate the pathway from gut microbiota to neuropathic pain has not been elucidated.
METHODS: We obtained the summary data of 412 gut microbiota, 731 immune cells, 91 inflammatory factors, and five types of neuropathic pain (drug-induced neuropathy, postherpetic neuralgia, sciatica, trigeminal neuralgia, and unspecified neuralgia) from large-scale genome-wide association study (GWAS) datasets and the FinnGen database. We used bidirectional Mendelian randomization (MR) analysis to explore the causal association between gut microbiota and neuropathic pain. Additionally, we conducted a mediation analysis to identify whether immune cells and inflammatory factors act as mediators within these causal relationships.
RESULTS: Our study revealed 30 causal relationships between 26 gut bacterial taxa and five types of neuropathic pain, including four associated with drug-induced neuropathy, six with postherpetic neuralgia, five with sciatica, eight with trigeminal neuralgia, and seven with unspecified neuralgia. Moreover, we identified 35 gut bacterial pathway abundances causally involved in neuropathic pain. The reverse MR analysis showed no evidence of reverse causality from gut microbiota to neuropathic pain. Mediation analysis demonstrated that the immune cell phenotype "HLA-DR++ monocyte % leukocyte" mediated the causal relationship between p_Proteobacteria and sciatica with a mediation proportion of 36.15% (P = 0.038), whereas "CD11c on CD62L+ myeloid dendritic cell" mediated the causal pathway from assimilatory sulfate reduction to trigeminal neuralgia with a mediation proportion of 27.90% (P = 0.041).
CONCLUSION: This study identified the causal relationships between several specific gut microbiota and various neuropathic pain subtypes. Additionally, two immune cells may act as potential mediators in the pathways from gut microbiota to neuropathic pain.
The invention relates to the technical field of medical instruments, in particular to a washing-disinfecting liquid and a disinfecting-washing bag thereof for skin and wounds with radionuclide contamination. The invention discloses a washing-disinfecting liquid for radioactive skin contamination, which is characterized in that the washing-disinfecting liquid contains 0.5 to 10 percent of EDTA, 0.5 to 10 percent of citric acid, 0.5 to 10 percent of super sodium chloride, and 0.5 to 10 percent of aqueous solution of fatty alcohol sodium sulfate. The invention also discloses a washing-disinfecting bag for radioactive skin contamination, which is characterized in that the washing-disinfecting bag comprises the washing-disinfecting liquid. The washing-disinfecting liquid has the advantages of high decontamination rate and no stimulation to skin or wounds. The washing-disinfecting bag adopting disposable packaging has the characteristics of small volume, convenience for carrying and storage and convenient quick use. When the radionuclide contamination of the skin and the wounds is removed, the washing-disinfecting liquid and the disinfecting-washing bag need no washing, produce little secondary pollution, and ensure good decontamination effects, so the washing-disinfecting liquid and the disinfecting-washing bag can be allocated to personnel engaged in nuclear power, nuclear reactors, radiation devices and other radiation work in the army or local places in order to implement radioactive washing and disinfecting in nuclear accident emergency.
A timed release medicament is produced by forming gel granules of a water-insoluble metal soap having particles of a therapeutic agent 50 embedded or enmeshed therein as to provide a predetermined release pattern.  Three ways of producing these granules are specified: (1) The therapeutic agent and metal soap are gelled in an organic solvent and the greater part of the solvent evaporated from the gel which is then broken up into small pieces and the remaining solvent evaporated.  (2) A solvent gel of the metal soap is prepared and the therapeutic agent added thereto after gel formation, the whole being subsequently kneaded to prepare a dough-like product which is screened and dried.  (3) A gel is prepared as in (2) and dried and screened.  Therapeutic agent in particulate form is intimately mixed and the mixture then compressed into tablets.  A highly water-soluble substance, such as lactose, may be incorporated in the gel.  The gel may also be produced by compression.  A surface-active agent (many specified) may be incorporated to increase the rate of release of therapeutic agent.  Many therapeutic agents, metal soaps and organic solvents are specified.
The Evidence-Based protocol will be identical to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants will complete 18 unsupervised home sessions and 12 supervised sessions over the course of 6-weeks.
Helicobacter pylori (H pylori) eradication is expected to effectively prevent gastric cancer (GC). However, GC cases may occur even longer than 10 years after H pylori eradication (L10AE). Moreover, the associated factors and characteristics are unknown. In this retrospective, single-center study conducted between 2017 and 2022, patients with GC diagnosed after H pylori eradication were enrolled and categorized into groups according to whether they were shorter than 10 years after H pylori eradication (S10AE) or L10AE. Patients were also categorized according to the depth of cancer invasion. Clinical data, pathological data, and risk factors were analyzed using logistic regression. Clinicopathological characteristics of GC diagnosed at L10AE and those invading the submucosal tissue or deeper (SMD) were investigated. In total, 202 cases of GC occurring after H pylori eradication were identified. Comparison of 158 S10AE and 44 L10AE GC cases revealed a significantly longer surveillance interval (SI) in L10AE cases (median: 2.0 vs 1.0 years, P = .01). Comparison of 150 intramucosal and 52 SMD GC cases revealed that L10AE GC cases were significantly more frequent amongst the SMD cases (18.0% vs 32.7%, P = .03). Pathologically, undifferentiated and mixed types were significantly more frequent in GC cases with SMD invasion (P < .001). Multivariate analysis revealed that L10AE was significantly related to GC cases with SMD invasion (odds ratio, 2.45; 95% confidence interval, 1.15-5.11; P = .019). SI was significantly longer in GC that developed at L10AE than at S10AE. In addition, GC with SMD invasion was more frequently detected in L10AE than in S10AE. Our data indicated that SI should not be groundlessly extended in patients at L10AE.
A method of separating actin from an intimate mixture of polymerized actin and myosin, e.g. solid actomyosin, raw muscle from which part of the myosin may have been removed by potassium chloride-phosphate solution, comprises reversibly depolymerizing the actin with an aqueous solution containing 10-4 to 10-3 mol. adenosine triphosphate and 0.5 to 0.8 mol. potassium or sodium iodide or thiocyanate at a temperature below 25 DEG  C. and preferably from 0 DEG  to 5 DEG  C. If the iodide is used, a minute portion of thiocyanate should be present, and if the thiocyanate is used, the presence of a minute portion of potassium chloride is desirable.  A supernatant phase is obtained to which a water-soluble precipitating agent capable of selectively precipitating the myosin without denaturing the depolymerized actin, e.g. ethyl or methyl alcohol, acetone, may be added, or the supernatent phase may be diluted with water to precipitate the repolymerized actin as actomyosin which is redissolved in aqueous potassium iodide solution containing a minute portion of adenosine triphosphate and the myosin is precipitated from the solution as above.  Actin may be recovered from the liquid phase by dialysis, e.g. against a phosphate buffer solution, or by isoelectric precipitation in the absence of salts.  Raw muscle tissue, when used, contains sufficient adenosine triphosphate for the depolymerization and it will be unnecessary to add any additional triphosphate.  Complete polymerization of the actin can be induced by addition of a small amount of potassium chloride.
This invention describes compounds active against TNF-.alpha. mRNA.  It further describes RNA molecules capable of conferring stability to RNA in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.
Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and medial supraclavicular node. Treatment will be given by normfractionated or hypofractionated radiotherapy (50Gy/25Fx/5w or 42.5Gy/16Fx/3.5w). IMRT and VMAT technique are recommended.
Half of the HS/EHS educators will be assigned to a waitlisted control group. Specifically, these educators will be scheduled to receive the intervention after a 6-month waiting period. During the interim period, they will complete the same assessments as Arm 1, but will continue to receive 'business as usual' support and professional development through typical Head Start/EHS programming.
BACKGROUND: Bone metastasis is the most common cause of cancer-related pain. Radiation therapy (RT) can provide successful palliation but there is currently no consensus for surveillance after palliative radiation. This study aimed to assess the feasibility of surveillance after RT for painful bone metastases.
METHODS: The study took place in an academic cancer center. Patient feasibility measures included % of calls answered, ease of recruitment and study retention. Clinician measures included % of calls made within 3 days, call time and qualitative feedback. Patients were identified with a painful bone metastasis treated with RT. The bone metastasis had a worst pain score of at least 4 (0-10 scale), with pain localized to a radiographically confirmed lesion. Patients were called at weeks 1, 4 and 8 following RT. Pain response and opioid use were assessed. Quality of life was assessed using a validated questionnaire. Descriptive statistics were used to assess if these metrics were met for patients and clinicians over 8 weeks post-RT.
RESULTS: Twenty patients were consented: 14 participants completed treatment and were not hospitalized or deceased prior to week 1. The patients were 50% male and 50% female. Recruitment was completed quickly, with no patients withdrawing. Response rate was week 1: 85% week 4: 83% and week 8: 83%. Six patients were referred back to their provider for pain management. Calls were made to patients within 3 days a median of 63% of the time (range, 40-82%), with a median call time of 16 (range, 8-42) minutes. Call lengths were longer for patients who required interpretation. Nurse feedback highlighted length of call and nursing time available as limitations.
CONCLUSIONS: All patient feasibility measures were met. Six patients required further pain management, highlighting a need for improved follow up post-RT for bone metastases. Staffing challenges for this intervention must be overcome.
Risk Summary

There are no data on the presence of tolvaptan or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Tolvaptan is present in rat milk (see Data). When a drug is present in animal milk, it is possible that the drug will be present in human milk, but relative levels may vary (see Data). Because of the potential for serious adverse reactions, including electrolyte abnormalities (e.g., hypernatremia), hypotension, and volume depletion in breastfed infants, advise women not to breastfeed during treatment with tolvaptan.

Data

In lactating rats administered radiolabeled tolvaptan, lacteal radioactivity concentrations reached the highest level at 8 hours after administration and then decreased gradually with time with a half-life of 27.3 hours. The level of activity in milk ranged from 1.5-to 15.8-fold those in maternal blood over a period of 72 hours post-dose. Increased perinatal death and decreased body weight of the offspring were observed during the lactation period and after weaning at approximately 11 times the exposure in CHF patients at the MRHD of 60 mg.
Probiotic supplement: Mix of probiotic strails. Administration: 1 stick per day or 5 drops per day. Study duration for each patient: 14 days.